Precigen: First patient dosed in Phase 1/1b study of of PRGN-3007

Precigen announced that the first patient has been dosed in the Phase 1/1b dose escalation/dose expansion study of PRGN-3007 in advanced ROR1-positive hematological and solid tumors. The target patient population for the study includes chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and diffuse large B-cell lymphoma and solid tumors, including breast adenocarcinomas encompassing triple negative breast cancer. There are estimated to be more than 100,000 patients diagnosed in both the hematological and TNBC target populations in the United States, European Union and Japan in 2023.